Key Highlights
- 62 percent of 77 patients in the carcinoma in situ cohort achieved a complete response, the data behind the FDA decision on October 14, 2026 to widen the Anktiva label for ImmunityBio (NASDAQ:IBRX) to papillary-only bladder cancer. It rests on extrapolation, not a new papillary trial.
- 0.8899 was the p-value on the primary endpoint when Vanda Pharmaceuticals (NASDAQ:VNDA) reported its VQW-765 social anxiety trial on October 14, 2026. The Phase 3 study of 546 adults missed both its primary and key secondary endpoints, and the program is on hold.
- October 17, 2026 is the FDA goal date for MR-141, phentolamine ophthalmic solution 0.75 percent, a presbyopia drop. Viatris (NASDAQ:VTRS) holds exclusive US commercial rights, and its market capitalization is about USD 20.4 billion in published market data.
- USD 89 million of cash at June 30, 2026, plus about USD 120 million available under a note agreement, is the runway Opus Genetics (NASDAQ:IRD) cites into 2029. The same MR-141 decision on October 17 is the partnered catalyst.
ImmunityBio (NASDAQ:IBRX)
The FDA expanded approval of Anktiva, given with BCG, on October 14, 2026 to adults with BCG-unresponsive non-muscle invasive bladder cancer whose tumors are papillary-only, which ImmunityBio calls the first approval for that group. The original April 2024 approval covered carcinoma in situ. The agency reportedly extended the label because carcinoma in situ and high-grade papillary disease behave alike, so no new papillary trial was required. Supporting data: 62 percent of 77 patients had a complete response, 58 percent of responders held it for at least 12 months and 40 percent for at least 24 months. The company says papillary disease is about 85 percent of this bladder cancer population. ImmunityBio (NASDAQ:IBRX) rose 5.36 percent to USD 10.32 during the session on October 14, and Jefferies kept Buy and lifted its target to USD 14 from USD 12 that day. One report shows the stock at USD 9.94 on October 15, so intraday quotes conflict. Second quarter net product revenue was USD 50.70 million, up 92 percent. The risk is commercial conversion: a broader label does not guarantee uptake, and an earlier refusal-to-file shows the path was bumpy. The European Society for Medical Oncology meeting runs October 23 to 27.
Vanda Pharmaceuticals (NASDAQ:VNDA)
Vanda announced after the close on October 14, 2026 that Study 3201 of VQW-765, a single oral dose for acute anxiety in social anxiety disorder, failed. Female participants scored 65.6 on the Subjective Units of Distress Scale with the drug against 66.0 with placebo, a difference of minus 0.4. The key secondary endpoint in all participants also missed, with a p-value of 0.6605. The result did not confirm an earlier Phase 2 study, a reminder that small mid-stage signals often fade in larger trials. Vanda (NASDAQ:VNDA) closed at USD 4.22 that day, then one report showed a 6.2 percent after-hours drop and another about 2 percent lower premarket on October 15, so the size of the reaction is unsettled. The balance sheet matters more: cash was USD 170.0 million at June 30, down USD 93.8 million since December 31, 2025, with a second quarter net loss of USD 62.5 million. Management says cash funds operations through at least 2027. Next catalysts are the Quimilza FDA date of December 12, 2026 and a December HETLIOZ hearing.
Viatris (NASDAQ:VTRS)
The FDA accepted Viatris's supplemental application on February 25, 2026, with an October 17, 2026 goal date for phentolamine ophthalmic solution 0.75 percent in presbyopia, the age-related loss of near focus. Viatris (NASDAQ:VTRS) holds exclusive US commercialization rights under a global license with Opus Genetics. The drug is already approved as Ryzumvi to reverse pharmacologically induced mydriasis, so this is a label expansion rather than a new molecule. Two Phase 3 trials, VEGA-2 and VEGA-3, met their primary and key secondary endpoints, according to the company, with no treatment-related serious adverse events and pupil effect lasting up to 20 hours. The company says presbyopia affects about 90 percent of US adults over 45, a prevalence figure, not a sales forecast. Published market data shows about USD 18.22 in October against a 52-week range of USD 9.69 to USD 18.43, so a good outcome may be partly priced. The risks are an FDA delay or complete response letter, and small revenue against a USD 20.4 billion company. Third quarter results come November 5, 2026.
Opus Genetics (NASDAQ:IRD)
Opus is the licensor behind MR-141, and the financial terms with Viatris have not been disclosed, so how much an approval is worth to Opus is unknown. Shares closed at USD 4.10 on October 14, 2026, down 3.30 percent, inside a 52-week range of USD 1.74 to USD 6.07. With roughly 83 million shares, the market value is about USD 340 million (simple arithmetic, not a published figure). The stock rose more than 50 percent on September 9 after early data from the low-dose cohort of its OPGx-BEST1 gene therapy trial. Enrollment in the OPGx-LCA5 Phase 3 trial finished in August. Opus (NASDAQ:IRD) held about USD 89 million of cash at June 30 and says that, plus note financing, lasts into 2029. A filed shelf registration in August signals future equity could be sold, which dilutes existing holders because new shares spread the same earnings over a bigger count. The October 17 outcome could affect royalty or milestone expectations, but the amounts remain unconfirmed.
Where Things Stand
It depends, but the nearest hard catalyst is the October 17, 2026 decision on MR-141, which touches Viatris (NASDAQ:VTRS). It also touches Opus Genetics (NASDAQ:IRD). ImmunityBio (NASDAQ:IBRX) already has its label expansion, so its next test is sales conversion and data at the October 23 to 27 oncology meeting. Vanda Pharmaceuticals (NASDAQ:VNDA) has the opposite situation, a failed trial that leaves its December 12, 2026 Quimilza date as the next event. The October 17 date is a Saturday, so the outcome may surface over the weekend or Monday. FDA goal dates can slip, and none of this is a forecast.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...